Cephalon
Executive Summary
Neuropharm R&D firm signs R&D and licensing agreement with Boston University for rights to key enzymes that may be partially responsible for development of amyloid plaques in Alzheimer's patients, West Chester, Pa.-based Cephalon announces. BU and the firm will work to identify the proteins and then design inhibitors to stop the development of amyloid plaques. New agreement should complement the $ 20 mil., five-year R&D agreement with Schering- Plough signed in June 1990 for development of brain protease inhibitors as Alzheimer's therapeutics. Cephalon said May 29 that it had received the second $ 5 mil. payment from the Schering agreement.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth